Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.82 USD
-0.02 (-0.52%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $3.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Aquestive Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
AQST 3.82 -0.02(-0.52%)
Will AQST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AQST
USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates
Other News for AQST
Commit To Buy Aquestive Therapeutics At $2.50, Earn 32.4% Annualized Using Options
Aquestive Therapeutics (AQST) Appoints New Chief Commercial Officer | AQST Stock News
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer | AQST Stock News
Aquestive Therapeutics promotes Korczynski to Chief Commercial Officer
Aquestive's Anaphylm to be reviewed by Health Canada